Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
The primary aim of the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) is to determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with CRVO, with the primary outcome of visual acuity measured at 6 months.
Participants with macular edema (swelling of the central part of the retina) associated with central retinal vein occlusion (CRVO) who are 18 years of age or older and are willing to provide consent are eligible for SCORE2.
Eighty (80) clinical centers across the continental U.S.
Regulatory Tracking System
Data Analysis and Reporting
Independent Data and Safety Monitoring Board Services
Meeting Coordination and Support
Site Selection and Contracting
Statistical Leadership and Project Management
Study Design/Protocol Development
Training and Certification
Web-based Data Collection and Reporting Systems